Live Breaking News & Updates on மல்டிபிளக்ஸ் மதிப்பீடு
Stay updated with breaking news from மல்டிபிளக்ஸ் மதிப்பீடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CDC to Replace Its PCR Test With One That Can Differentiate Between CCP Virus and Flu Posted on The Centers for Disease Control and Prevention (CDC) will no longer recommend its PCR test to detect the CCP virus, saying that it will withdraw the test’s emergency use authorization (EUA), and instead, encourage labs to use a multiplex assay that can detect and differentiate the virus from the flu. “Given the availability of commercial options, CDC intends to discontinue support for the CDC 2019 Novel Coronavirus (2019 nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2,” Jasmine Reed, public affairs specialist at the CDC, told The Epoch Times via email. ....
CDC to Replace Its PCR Test With One That Can Differentiate Between CCP Virus and Flu theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.
The CDC's Withdrawal of EUA for the RT-PCR Tests Does Not Mean the Test Failed Review pjmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pjmedia.com Daily Mail and Mail on Sunday newspapers.
Global Antibody Market Expected to Reach USD 318,482.1 Million by 2027, With a CAGR Of 10.1% prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Promega Corporation: SARS-CoV-2 Antibody Test Developed by Promega Receives CE Mark Novel bioluminescent Lumit Dx SARS-CoV-2 Immunoassay enables simple, scalable antibody detection A SARS-CoV-2 antibody test developed by Promega Corporation, the Lumit Dx SARS-CoV-2 Immunoassay, has received CE marking and is now available in Europe. The novel bioluminescent immunoassay is a qualitative in vitro diagnostic test intended to detect antibodies to SARS-CoV-2 in serum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005062/en/ The Lumit Dx SARS-CoV-2 Immunoassay by Promega has received CE marking. The novel bioluminescent immunoassay is a qualitative in vitro diagnostic test intended to detect antibodies to SARS-CoV-2 in serum. (Photo: Business Wire) ....